CareDx, Inc (CDNA)

7,76 -0,44 (-5,37 %) À la clôture : 04:00PM EDT

CareDx, Inc

8000 Marina Boulevard
Brisbane
South San Francisco, CA 94005
United States
415 287 2300
https://caredx.com

Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein: 635

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Abhishek Jain	CFO & Principal Accounting Officer	425,58k	S.O.	1977
Dr. Peter Maag Ph.D.	Executive Director	43,23k	S.O.	1967
Mr. Alexander L. Johnson	President of Patient & Testing Services	547,43k	S.O.	1974
Mr. John Walter Hanna Jr.	President, CEO & Director	S.O.	S.O.	1980
Ms. Marica Grskovic Ph.D.	Chief Operating Officer	S.O.	S.O.	S.O.
Dr. Robert N. Woodward Ph.D.	Chief Scientific Officer	S.O.	S.O.	S.O.
Mr. GS Jha	Senior VP, Chief Information Officer & Chief Information Security Officer	S.O.	S.O.	S.O.
Jeffrey A. Novack	General Counsel	S.O.	S.O.	S.O.
Ms. Stacey Follon	Senior VP & Head of Human Resources	S.O.	S.O.	S.O.
Mr. Kashif Rathore	Chief of Patient & Digital Solutions	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de CareDx, Inc en date du 29 avril 2024 est 6. Les scores principaux sont Audit : 10; Société : 3; Droits des actionnaires : 5; Compensation : 6.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.